Back to Browse Journals » Clinical Interventions in Aging » Volume 3 » Issue 2

Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems

Authors Randi J Hagerman, Deborah A Hall, Sarah Coffey, Maureen Leehey, James Bourgeois, et al

Published Date June 2008 Volume 2008:3(2) Pages 251—262

DOI http://dx.doi.org/10.2147/CIA.S1794

Published 30 June 2008

Randi J Hagerman1,2, Deborah A Hall3, Sarah Coffey1,2, Maureen Leehey3, James Bourgeois4, John Gould5, Lin Zhang6, Andreea Seritan4, Elizabeth Berry-Kravis7–9, John Olichney6, Joshua W Miller10, Amy L Fong11, Randall Carpenter12, Cathy Bodine13, Louise W Gane1,2, Edgar Rainin1, Hillary Hagerman1, Paul J Hagerman14

1M.I.N.D. Institute, 2Department of Pediatrics, 4Department of Psychiatry & Behavioral Sciences, 5Department of Urology, 6Department of Neurology, 10Department of Pathology and Laboratory Medicine, 14Department of Biochemistry and Molecular Medicine, University of California, Davis, School of Medicine, Sacramento, CA, USA; 3Department of Neurology, University of Colorado, Denver, CO, USA; 7Department of Pediatrics, Neurology, and Biochemistry, 8Department of Neurological Sciences, 9Department of Biochemistry, Rush University Medical Center, Chicago, IL, USA; 11Physical Edge, Inc., Davis, CA, USA; 12Seaside Therapeutics, Cambridge, MA, USA; 13Department of Physical Medicine and Rehabilitation, University of Colorado Health Sciences Center, Denver, CO, USA

Abstract: Fragile X-associated tremor/ataxia syndrome (FXTAS) is a progressive neurological disorder that affects older adult carriers, predominantly males, of premutation alleles (55 to 200 CGG repeats) of the fragile X (FMR1) gene. Principal features of FXTAS are intention tremor, ataxia, parkinsonism, cognitive decline, and peripheral neuropathy; ancillary features include, autonomic dysfunction, and psychiatric symptoms of anxiety, depression, and disinhibition. Although controlled trials have not been carried out in individuals with FXTAS, there is a significant amount of anecdotal information regarding various treatment modalities. Moreover, there exists a great deal of evidence regarding the efficacy of various medications for treatment of other disorders (eg, Alzheimer disease) that have substantial phenotypic overlap with FXTAS. The current review summarizes what is currently known regarding the symptomatic treatment, or potential for treatment, of FXTAS.

Keywords: fragile X syndrome, dementia, ataxia, neurodegeneration, parkinsonism, tremor

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Modulation of the GABAergic pathway for the treatment of fragile X syndrome

Lozano R, Hare EB, Hagerman RJ

Neuropsychiatric Disease and Treatment 2014, 10:1769-1779

Published Date: 16 September 2014

Readers of this article also read:

Evaluation of glycophenotype in breast cancer by quantum dot-lectin histochemistry

Andrade CG, Cabral Filho PE, Tenorio DPL, Santos BS, Beltrão EIC, Fontes A, Carvalho Jr LB

International Journal of Nanomedicine 2013, 8:4623-4629

Published Date: 2 December 2013

Therapeutic efficiency of folated poly(ethylene glycol)-chitosan-graft-polyethylenimine-Pdcd4 complexes in H-ras12V mice with liver cancer

Kim YK, Minai-Tehrani A, Lee JH, Cho CS, Cho MH, Jiang HL

International Journal of Nanomedicine 2013, 8:1489-1498

Published Date: 16 April 2013

Gemcitabine-loaded liposomes: rationale, potentialities and future perspectives

Federico C, Morittu VM, Britti D, Trapasso E, Cosco D

International Journal of Nanomedicine 2012, 7:5423-5436

Published Date: 1 November 2012

Medicine at nanoscale: a new horizon

Khan AU

International Journal of Nanomedicine 2012, 7:2997-2998

Published Date: 18 June 2012

Impact of nanotechnology in cancer: emphasis on nanochemoprevention

Siddiqui IA, Adhami VM, Chamcheu JC, Mukhtar H

International Journal of Nanomedicine 2012, 7:591-605

Published Date: 2 February 2012

Improvement of sensorimotor functions in old age by passive sensory stimulation

Tobias Kalisch, Martin Tegenthoff, Hubert R Dinse

Clinical Interventions in Aging 2008, 3:673-690

Published Date: 5 August 2008

Vocal aging and adductor spasmodic dysphonia: Response to botulinum toxin injection

Michael P Cannito, Joel C Kahane, Lesya Chorna

Clinical Interventions in Aging 2008, 3:131-151

Published Date: 26 March 2008

Can cellulite be treated with low-energy extracorporeal shock wave therapy?

Fiorenzo Angehrn, Christoph Kuhn, Axel Voss

Clinical Interventions in Aging 2007, 2:623-630

Published Date: 3 January 2007